Cyclacel Pharmaceuticals Inc. Overview

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company operating within the health care sector, is primarily focused on biotechnology. The company is based in Berkeley Heights, United States, and extends its services to customers in both the United States and the United Kingdom. Cyclacel’s mission is to discover and develop small molecule cycle inhibitors aimed at the effective treatment of cancer and other serious diseases. This mission is pursued through rigorous research and development efforts. The company’s stock is publicly traded on the Nasdaq stock exchange, and more information can be found on their official website at www.cyclacel.com .

Financial Snapshot

As of July 31, 2025, Cyclacel Pharmaceuticals reported a close price of $9.72. The company’s market capitalization stands at $17,760,000 USD. Over the past year, the stock has experienced significant volatility, with a 52-week high of $597.6 on October 21, 2024, and a 52-week low of $3.08 on July 6, 2025. The price-to-earnings ratio is currently at -0.038, reflecting the company’s financial performance and market expectations.

Industry and Sector

Cyclacel Pharmaceuticals operates within the biotechnology industry, a segment of the broader health care sector. The company’s focus on developing small molecule cycle inhibitors positions it as a key player in the ongoing battle against cancer and other serious diseases. The biotechnology industry is known for its intensive research and development activities, which are crucial for the advancement of medical treatments and therapies.

Conclusion

Cyclacel Pharmaceuticals, Inc. continues to focus on its mission to develop innovative treatments for serious diseases through its biotechnology initiatives. Despite recent stock volatility, the company remains committed to its research and development efforts, aiming to make significant contributions to the health care sector. For investors and stakeholders, Cyclacel’s activities and financial performance are closely monitored, given the potential impact of its research outcomes on the market and patient care.